Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Protagonist Therapeutics, Inc. - Common Stock
(NQ:
PTGX
)
50.40
-0.29 (-0.57%)
Streaming Delayed Price
Updated: 10:44 AM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Protagonist Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
June 30, 2025
Via
ACCESS Newswire
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
June 26, 2025
Via
ACCESS Newswire
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
June 01, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
May 21, 2025
Via
ACCESS Newswire
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 21, 2025
Via
ACCESS Newswire
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
November 19, 2024
Via
ACCESSWIRE
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
May 09, 2025
Via
ACCESS Newswire
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 06, 2025
Via
ACCESS Newswire
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
April 23, 2025
Via
ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Award
April 16, 2025
Via
ACCESS Newswire
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
April 10, 2025
Via
ACCESS Newswire
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 07, 2024
Via
ACCESSWIRE
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024
Via
ACCESSWIRE
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
March 18, 2025
Via
ACCESS Newswire
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
March 10, 2025
Via
ACCESS Newswire
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
March 08, 2025
Via
ACCESS Newswire
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
March 03, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
January 29, 2025
Via
ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Awards
January 06, 2025
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
December 19, 2024
Via
ACCESSWIRE
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
December 09, 2024
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
November 22, 2024
Via
ACCESSWIRE
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
November 21, 2024
Via
ACCESSWIRE
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
November 18, 2024
Via
ACCESSWIRE
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
November 05, 2024
Via
ACCESSWIRE
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
October 29, 2024
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
September 03, 2024
Via
ACCESSWIRE
RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
August 01, 2024
Via
ACCESSWIRE
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
July 31, 2024
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
July 22, 2024
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.